In the past five years, he has published 45 SCI papers as the first or corresponding author in Lancet Oncology, Journal of Clinical Oncology, Clinical Cancer Research, Journal of Thoracic Oncology and other international journals, with a cumulative impact factor of 330. Has obtained 4 scientific research achievements above the provincial level, which have been orally reported or exhibited in poster sessions at international conferences such as AACR, ASCO, WCLC and GAP, etc. Has published 46 conference papers, of which 3 are oral presentations, and has been mainly involved in the research and development of 5 original 1.1 new drugs, and has been approved for 3 patents.
Has participated in the compilation of the Chinese Society of Clinical Oncology Guidelines for the Diagnosis and Treatment of Primary Lung Cancer, the Chinese Society of Clinical Oncology Expert Consensus on Perioperative Treatment of Early-stage Lung Cancer, the Chinese Medical Association Clinical Guidelines for Lung Cancer, the Ministry of Health Guidelines for the Standardized Diagnosis and Treatment of Common Tumors in Municipal and County Hospitals, the Chinese Expert Consensus for Multidisciplinary Team Diagnosis and Treatment of Lung Cancer, and has also taken part in the formulation of the guiding principles of the CDEs clinical trials of many anticancer drugs. As a principal investigator, he has designed, organized and participated in nearly 300 Phase I-III clinical trials, with more than 30 clinical studies in progress, and has led clinical studies on a number of innovative anti-cancer drugs as Leading PI.